Clinical evidence supporting the efficacy, safety and efficiency of Atraverse Medical’s Hotwire left-heart access system was presented recently at the 30th annual AF symposium (16–18 January 2025, Boston, USA), the company has announced.
Atraverse states in a press release that it developed Hotwire in response to the demand for enhanced procedural efficiency and streamlined workflows with a therapy-agnostic left-heart access innovation.
Two late-breaking posters featured at the AF symposium detailed preclinical research and first-in-human clinical experience relating to the safety and efficacy of Hotwire—one entitled, “First-in-human multicentre experience using a novel radiofrequency transseptal wire”, presented by Devi Nair (St Bernards Medical Center, Jonesboro, USA), and another entitled, “Impedance-based energy cessation reduces overall energy duration during radiofrequency-powered transseptal puncture”, presented by Jeremiah Wasserlauf (Endeavor Health, Chicago, USA).
Nair, who was the first clinician in the world to use Hotwire in practice, commented: “It is exciting to see the preclinical results of the Hotwire translate to the clinical environment. The early experience confirms a favourable safety profile and efficient workflow.”
Eric Sauter, chief operating officer (COO) and co-founder of Atraverse, and first named inventor of the Hotwire technology, added: “We have conducted sustained and rigorous biomedical research in developing the Hotwire in order to deliver a safe, efficient and easy-to-use product. These findings validate our teams’ execution of these efforts along with the market need for improved technology in this space.”
Utilised in more than 130 successful procedures nationwide since its US Food and Drug Administration (FDA) clearance in May 2024, Atraverse’s Hotwire device is a novel radiofrequency guidewire that enables zero-exchange left-heart access while acting as a rail for catheter-based therapy systems. With universal sheath compatibility, Hotwire is designed to advance transseptal access technology, optimise procedural workflows and improve patient outcomes, as per a company press release.
